Rakovina Therapeutics Unleashes Results from Historic 2023 Annual General Meeting!

At its 2023 annual general meeting of shareholders held on June 28, 2023, Rakovina Therapeutics Inc. (TSXV: RKV) was pleased to announce the re-election of its four board members named in its management information circular, namely Jeffrey Bacha, Dr. Dennis Brown, Alfredo De Lucrezia and Michael Liggett. Furthermore, shareholders also approved the appointment of Davidson & Company LLP as the Company’s auditor until the next annual meeting, as well as the approval of the Company’s existing omnibus equity incentive plan.

A sign of confidence in Rakovina’s commitment to advancing novel DNA-damage response technologies for the development of new cancer therapies, these results mark a promising start to the year for the biopharmaceutical company.

About Rakovina Therapeutics Inc.

Rakovina Therapeutics Inc. is revolutionizing the fight against cancer with its innovative DNA-damage response technologies. Through its advanced pipeline of novel inhibitors, the company is committed to making a tangible improvement to patient outcomes and taking therapeutic treatments beyond the laboratory and onto the global market.

By obtaining clearance from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies, Rakovina Therapeutics aims to bring its life-saving candidate drugs into clinical trials and make them available to those in need.

Leave a Comment